Breaking Finance News

Zacks Investment Research downgraded Recro Pharma Inc (NASDAQ:REPH) to Sell in a report released today.

Only yesterday Recro Pharma Inc (NASDAQ:REPH) traded 2.04% higher at $8.60. REPH’s 50-day average is $9.32 and its 200-day moving average is $7.76. With the last close up 22.47% from the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. Trade volume was was up over the average, with 53,177 shares of REPH changing hands over the typical 41,133 shares..

Zacks Investment Research has downgraded Recro Pharma Inc(NASDAQ:REPH) to Sell in a statement released 8/18/2016.

Previously on 6/19/2015, Brean Murray reported on Recro Pharma Inc(NASDAQ:REPH) bumped the target price from $26.00 to $28.00. At the time, this suggested an upside of 1.13%.

See Graph Below:

Recro Pharma Inc (NASDAQ:REPH)

Recro Pharma Inc has a one-year low of $5.59 and a one-year high of $17.20 . Recro Pharma Inc’s total market value is presently $0.0.

About Recro Pharma Inc (NASDAQ:REPH)

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, and which can occur in diabetic patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.